Diafragmatic Hernia

11/8/2010 Congenital Diaphragmatic Hernia: [Print] - eMedicin…
emedicine.medscape.com
eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Neonatology
Congenital Diaphragmatic Hernia

Robin H Steinhorn, MD, Raymond and Hazel Speck Berry Professor of Pediatrics, Division Head of Neonatology, Associate Chair of Pediatrics, Northw estern University School
of Medicine
Nicolas FM Porta, MD, FAAP, Assistant Prof essor, Department of Pediatrics, Northw estern University, The Feinberg School of Medicine
Updated: Oct 13, 2010
Introduction
Background
The topic of congenital diaphragmatic hernia (CDH) has frequently appeared in the medical literature since its first description in the early 18th century.
Initial theories about the pathophysiology of this condition centered on the presence of the herniated viscera within the chest and the need for its
prompt removal.
In 1946, Gross reported the first successful repair of a neonatal diaphragmatic hernia in the first 24 hours of life.[1 ]The medical literature for the next
decade addressed congenital diaphragmatic hernia as a surgical problem and discussed various technical aspects of surgical repair, including
techniques required to close large defects. In the 1960s, however, Areechon and Reid observed that the high mortality rate of congenital diaphragmatic
hernia was related to the degree of pulmonary hypoplasia at birth.[2 ]
Over the past 20 years, pulmonary hypertension and pulmonary hypoplasia have been recognized as the 2 cornerstones of the pathophysiology of
congenital diaphragmatic hernia. In recent years, evidence suggests that cardiac maldevelopment may further complicate the pathophysiology of
congenital diaphragmatic hernia.[3 ]
Radiograph of a 1-day-old infant with a moderate-sized congenital diaphragmatic hernia (CDH). Note the air- and fluid-filled bowel
loops in the left chest, the moderate shift of the mediastinum into the right chest, and the position of the orogastric tube.
Pathophysiology
The 3 basic types of congenital diaphragmatic hernia include the posterolateral Bochdalek hernia (occurring at approximately 6 weeks' gestation), the
anterior Morgagni hernia, and the hiatus hernia. The left-sided Bochdalek hernia occurs in approximately 85% of cases. Left-sided hernias allow
herniation of both the small and large bowel and intraabdominal solid organs into the thoracic cavity. In right-sided hernias (13% of cases), only the
http://emedicine.medscape.com/article/978118-print 1/15
liver and a portion of the large bowel tend to herniate. Bilateral hernias are uncommon and are usually fatal. [4 ]
Congenital diaphragmatic hernia is characterized by a variable degree of pulmonary hypoplasia associated with a decrease in cross-sectional area of
the pulmonary vasculature and alterations of the surfactant system. The lungs have a small alveolar capillary membrane for gas exchange, which may
be further decreased by surfactant dysfunction. In addition to parenchymal disease, increased muscularization of the intraacinar pulmonary arteries
appears to occur. In very severe cases, left ventricular hypoplasia is observed. Pulmonary capillary blood flow is decreased because of the small cross-
sectional area of the pulmonary vascular bed, and flow may be further decreased by abnormal pulmonary vasoconstriction.
Frequency
International
Congenital diaphragmatic hernia occurs in 1 of every 2000-3000 live births and accounts for 8% of all major congenital anomalies. The risk of
recurrence of isolated (ie, nonsyndromic) congenital diaphragmatic hernia in future siblings is approximately 2%.[5 ]Familial congenital diaphragmatic
hernia is rare (<2% of all cases), and both autosomal recessive and autosomal dominant patterns of inheritance have been reported. Congenital
diaphragmatic hernia is a recognized finding in Cornelia de Lange syndrome and also occurs as a prominent feature of Fryns syndrome, an autosomal
recessive disorder with variable features, including diaphragmatic hernia, cleft lip or palate, and distal digital hypoplasia.
Mortality/Morbidity
Mortality has traditionally been difficult to determine. This is partially because of the "hidden mortality" for this condition, which refers to infants with
congenital diaphragmatic hernia who die in utero or shortly after birth, prior to transfer to a surgical site. This bias may be especially important when
evaluating institutional reports of outcome.
A population-based study from Western Australia indicated that only 61% of infants with congenital diaphragmatic hernia are live born. In that study,
nearly 33% of pregnancies that involved a fetus with congenital diaphragmatic hernia were electively terminated. Most of the pregnancies (71%) were
terminated because of the presence of another major anomaly.
Mortality after live birth is generally reported to range from 40-62%, and some authors argue that the true mortality of congenital diaphragmatic hernia
has not changed with introduction of new therapies. The presence of associated anomalies has consistently been associated with decreased survival;
other associations with poor outcome include prenatal diagnosis, prematurity, low birth weight, and early pneumothorax.
Keller et al found that infants with congenital diaphragmatic hernia who have poor outcomes (death or discharge on oxygen) have higher plasma levels
of endothelin-1, which is dysregulated in pulmonary hypertension. [6 ]Severity of pulmonary hypertension was also associated with increasing
endothelin-1 levels.
Sex
Most studies report that congenital diaphragmatic hernia occurs equally in males and females.
Age
Although congenital diaphragmatic hernia is usually a disorder of the newborn period, as many as 10% of patients may present after the newborn
period and even during adulthood. Outcome in patients with late presentation of congenital diaphragmatic hernia is extremely good, with low or no
mortality.
Clinical
History
As noted in Mortality/Morbidity, population-based studies show that congenital diaphragmatic hernia (CDH) is diagnosed based on prenatal
ultrasonography findings in approximately one half of affected infants. Infants may have a prenatal history of polyhydramnios.
Infants most commonly present with respiratory distress and cyanosis in the first minutes or hours of life, although a later presentation is possible. The
respiratory distress can be severe and may be associated with circulatory insufficiency, requiring aggressive resuscitative measures.
Physical
Infants frequently exhibit a scaphoid abdomen, barrel-shaped chest, and signs of respiratory distress (retractions, cyanosis, grunting respirations).
In left-sided posterolateral hernia, auscultation of the lungs reveals poor air entry on the left, with a shift of cardiac sounds over the right chest. In
patients with severe defects, signs of pneumothorax (poor air entry, poor perfusion) may also be found.
Associated anomalies occur in a relatively high percentage of infants. Dysmorphisms such as craniofacial, extremity abnormalities, or spinal
dysraphism may suggest syndromic congenital diaphragmatic hernia.
Causes
The diaphragm initially develops as a septum between the heart and liver, progresses posterolaterally, and closes at the left Bochdalek foramen at
approximately 8-10 weeks' gestation.
The herniation of viscera in severe congenital diaphragmatic hernia is believed to occur during the pseudoglandular stage of lung development. Lung
compression results in pulmonary hypoplasia that is most severe on the ipsilateral side, although both lungs may be abnormal. Pulmonary hypoplasia
is associated with fewer bronchial generations, alveoli, and arterial generations.
Congenital diaphragmatic hernia can be induced in rat models with administration of the herbicide toxin nitrofen. Studies in these models show that the
diaphragmatic defect occurs in the initial stages of diaphragm development, rather than in the later stages.
Fetal exposure to nitrofen causes a variable amount of lung hypoplasia. The fact that only 60-90% of exposed rat pups demonstrate diaphragmatic
defects suggests a “dual-hit” hypothesis, in which 2 insults (one primarily affecting the lungs and another primarily affecting diaphragm development)
contribute to the pathophysiology of congenital diaphragmatic hernia.
Congenital diaphragmatic hernia may occur as a nonsyndromic or isolated defect. Less than 2% of such cases are estimated to be familial. Pedigrees
consistent with autosomal recessive, autosomal dominant, and X-linked inheritance patterns have been described.
More than 10% of infants with congenital diaphragmatic hernia have an underlying syndromic diagnosis, although few gene mutations are currently
recognized. Congenital diaphragmatic hernia is a recognized finding of Cornelia de Lange syndrome, an autosomal dominant syndrome with
characteristic facial features, hirsutism, and developmental delay. Fryns syndrome is an autosomal recessive condition that includes congenital
diaphragmatic hernia as the cardinal feature, along with hypoplasia of the distal digits and other variable abnormalities of the brain, heart, and
genitourinary development. An associated gene has not yet been identified, and the prognosis of Fryns syndrome is poor.
Chromosome abnormalities have been reported in as many as 30% of infants with congenital diaphragmatic hernia, which has been described as part
of trisomy 13, trisomy 18, trisomy 21, and Turner syndrome (monosomy X). Pallister-Killian syndrome (tetrasomy 12p mosaicism) presents with
findings that are similar to those of Fryns syndrome, including coarse facial features, aortic stenosis, cardiac septal defects, and abnormal genitalia.
This diagnosis can only be made if a karyotype is determined based on skin biopsy findings.
Chromosome deletions on chromosomes 1q, 8p, and 15q have been reported in association with congenital diaphragmatic hernia. Deletions of
chromosomes 8p and 15q appear to be associated with heart malformations.
Deficiencies in vitamin A availability, metabolism, and signaling have been found to contribute to the development of congenital diaphragmatic hernia in
animal models and may also be relevant in human fetal development. [7 ]
Differential Diagnoses
Cystic Adenomatoid Malformation
Disorders of the Thoracic Cavity and Pleura
Pneumothorax
Pulmonary Hypertension, Persistent-Newborn
Other Problems to Be Considered

Bronchopulmonary sequestration
Workup
Laboratory Studies
Several studies may be indicated in congenital diaphragmatic hernia (CDH).
Obtain frequent ABG measurements to assess for pH, PaCO2, and PaO2. Note the sampling site because persistent pulmonary hypertension of the
newborn (PPHN) with right-to-left ductal shunting often complicates CDH. The PaO2 is often higher from a preductal (right-hand) sampling site.
Serum lactate may be helpful in assessing for circulatory insufficiency or severe hypoxemia associated with tissue hypoxia.
Obtain chromosome studies, including microarray analysis, because of the frequent association with chromosomal anomalies. In rare cases (eg,
Pallister-Killian syndrome), chromosomal disorders that can be diagnosed only based on skin biopsy findings may be present. If dysmorphic features
are observed upon examination, a consultation with a geneticist is often helpful in evaluating the infant and ensuring that chromosome studies include
appropriate deletion analysis.
As with all critically ill neonates, monitor levels of serum electrolytes, ionized calcium, and glucose initially and frequently. Maintaining glucose levels
in the reference range and maintaining calcium homeostasis are particularly important.
Imaging Studies
Obtain a chest radiograph if congenital diaphragmatic hernia is suspected (see the image below).
Radiograph of a 1-day-old infant with a moderate-sized congenital diaphragmatic hernia (CDH). Note the air- and fluid-filled bowel
loops in the left chest, the moderate shift of the mediastinum into the right chest, and the position of the orogastric tube.
Placement of an orogastric tube prior to the study helps decompress the stomach and helps determine whether the tube is positioned above or below
the diaphragm.
Typical findings in a left-sided posterolateral congenital diaphragmatic hernia include air-filled or fluid-filled loops of the bowel in the left hemithorax and
shift of the cardiac silhouette to the right. Examine the chest radiograph for evidence of pneumothorax.
The incidence of associated cardiac anomalies is high (approximately 25%); therefore, cardiac ultrasonography is needed shortly after birth. Cardiac
defects may be relatively minor (atrial septal defect) or life-threatening (transposition of great vessels, hypoplastic left heart, aortic coarctation). In
addition, echocardiography is helpful in assessing myocardial function and determining whether the left ventricular mass is significantly decreased.
Genitourinary anomalies occur in 6-8% of infants with congenital diaphragmatic hernia; renal ultrasonography should be considered.
CNS defects (neural tube defects, hydrocephalus) may be associated with congenital diaphragmatic hernia. Although MRI provides definitive diagnostic
information, bedside cranial sonography is generally performed when an infant is considered for extracorporeal support. In that circumstance, the goal
is to evaluate for intraventricular bleeding and hypoxic-ischemic changes, as well as to rule out major intracranial anomalies.
Other Tests
Continuous pulse oximetry is valuable in the diagnosis and management of PPHN. Place oximeter probes at preductal (right-hand) and postductal
(either foot) sites to assess for a right-to-left shunt at the ductus arteriosus level.
Procedures
Endotracheal intubation and mechanical ventilation are required in all infants with severe congenital diaphragmatic hernia who present in the first hours
of life. If the diagnosis is known at the time of delivery, avoid bag-and-mask ventilation in the delivery room because the stomach and intestines
become distended with air and further compromise pulmonary function. A nasogastric tube should be placed as soon as possible to provide intestinal
decompression.
As discussed in Treatment, the goal is to adequately expand the lung but to avoid overdistension; therefore, inspiratory pressures should be kept as
low as possible. Consider the use of high-frequency ventilation (HFV) if high inspiratory pressures are required.
Place an indwelling catheter in the umbilical artery or in a peripheral artery (radial, posterior tibial) for continuous blood pressure and frequent ABG
monitoring.
Place a venous catheter via the umbilical vein to allow for administration of inotropic agents and hypertonic solutions such as calcium gluconate. If the
liver is in the chest, the catheter will likely not pass through the ductus venosus, and another route must be considered for central venous access.
The use of HFV in congenital diaphragmatic hernia remains controversial, and no randomized studies indicate a clear benefit. However, HFV may allow
for use of lower ventilator pressures and may help normalize PaCO2. Mean airway pressures should be carefully adjusted to avoid lung overdistension.
Frequent radiograph (with a goal of 8-9 rib expansion of the contralateral lung) may help in the ongoing assessment and optimization of lung
expansion.
Venoarterial or venovenous ECMO support is an adaptation of cardiopulmonary bypass and involves a surgical team; [8 ]insertion of catheters into the
internal jugular vein, internal carotid artery, or both; systemic heparinization; and oxygenation through the use of an artificial membrane lung. Because
of its complexity and resource expense, ECMO is available at fewer than 100 centers in the United States. The overall survival rate for infants with
congenital diaphragmatic hernia reported to the international Extracorporeal Life Support Organization (ELSO) registry is approximately 52%, which is
the lowest rate in all the neonatal conditions treated with ECMO. Although no conclusive evidence shows that ECMO improves survival or outcome for
infants with congenital diaphragmatic hernia, it remains a commonly used therapy for severely affected infants.
Histologic Findings
Both lungs appear abnormal, although histologic changes are more severe on the affected side. Bronchi are less numerous, and the overall number of
alveoli is reduced.
In addition, the lungs appear to be less mature with fewer mature alveoli. Pulmonary vascular abnormalities occur in addition to parenchymal
abnormalities, characterized by both a reduction in the cross-sectional area of the pulmonary vascular bed and an abnormal increase in
muscularization of pulmonary arteries and arterioles.
Treatment
Medical Care
Because of associated persistent pulmonary hypertension of the newborn (PPHN) and pulmonary hypoplasia, medical therapy in patients with
congenital diaphragmatic hernia (CDH) is directed toward optimizing oxygenation while avoiding barotrauma.
In the delivery room, if the infant is known or suspected to have congenital diaphragmatic hernia, immediately place a vented orogastric tube and
connect it to continuous suction to prevent bowel distension and further lung compression. For the same reason, avoid mask ventilation and
immediately intubate the trachea. Avoid high peak inspiratory pressures and be alert to the possibility of early pneumothorax if the infant does not
stabilize.[9 ]
Infants with congenital diaphragmatic hernia may have immature lung development, and animal studies have indicated that surfactant deficiency may
be present. However, reports from the Congenital Diaphragmatic Hernia Study Group indicate that administration of exogenous surfactant does not
improve survival, need for extracorporeal membrane oxygenation (ECMO), or long-term outcome. Interestingly, this finding is true for both term and
preterm infants with congenital diaphragmatic hernia.
Mechanical ventilation strategies are targeted at avoiding high peak inspiratory pressures and synchronizing ventilation with the infant's respiratory
effort. In some instances, high-frequency ventilation (HFV) may be helpful in avoiding the use of high peak inspiratory pressures, although this modality
is best used at a center with experience in assessing and maintaining optimal lung distension.
Infants with congenital diaphragmatic hernia are critically ill and require meticulous attention to detail for subsequent medical care, including
continuous monitoring of oxygenation, blood pressure, and perfusion. A minimal stimulation approach that reduces handling and invasive procedures,
such as suctioning, is suggested.
Maintain glucose and ionized calcium concentrations within reference range. If necessary, support blood pressure using volume expansion and
inotropic agents. An adequate circulating volume is necessary to maintain right ventricular filling and cardiac output; however, once circulating volume
is normalized, repeated boluses of crystalloid solutions, colloid solutions, or both do not provide additional benefit. Inotropic support with dopamine,
dobutamine, or milrinone may be helpful in maintaining adequate systemic blood pressure; dobutamine and milrinone may be particularly helpful if
myocardial dysfunction is present. Epinephrine infusions may be necessary in severe cases; low-dose epinephrine (<0.2 mcg/kg/min) may help to
promote pulmonary blood flow and improve cardiac output.
The appropriate targets for PaO2 and PaCO2 are controversial. PaO2 concentrations greater than 50 mm Hg typically provide for adequate oxygen
delivery at the tissue level. Aiming for higher PaO2 concentrations may lead to increased ventilator support and barotrauma. Similarly, infants with
congenital diaphragmatic hernia often have hypercarbia because of pulmonary hypoplasia. Whether to maintain a low PaCO2 for pulmonary
vasodilation, to allow permissive hypercapnia, or to maintain normocarbia remains controversial. No reliable controlled studies are known, and debate
continues in the medical literature. Retrospective studies suggest that gentle ventilation and allowing chronic mild hypercarbia may be associated with
improved survival.
Alkalinization was frequently used in the past because of its ability to produce a rapid pulmonary vasodilation. Forced alkalosis can be accomplished
either by using hyperventilation to induce hypocarbia or by alkali infusions. However, benefits of alkalosis have never been demonstrated in any
prospective clinical trial, and these therapies are considered controversial. In addition, alkalosis may result in undesirable side effects. For instance,
hypocarbia constricts the cerebral vasculature and reduces cerebral blood flow. Extreme alkalosis and hypocarbia are strongly associated with later
neurodevelopmental deficits, including a high rate of sensorineural hearing loss. Previous studies by Walsh-Sukys and colleagues indicates that the
use of alkali infusions may be associated with increased use of ECMO and an increased use of oxygen at age 28 days.[10 ]
Inhaled nitric oxide has revolutionized the treatment of PPHN but its benefit in the infant with congenital diaphragmatic hernia remains controversial.
Nitric oxide does not reduce mortality or the need for ECMO in infants with congenital diaphragmatic hernia, although it may immediately stabilize
infants with critical hypoxemia and reduce the chances of cardiopulmonary arrest. [11 ]Inhaled nitric oxide should be used with caution if ECMO is not
immediately available. New studies indicate a potential role for long-term low-dose inhaled nitric oxide therapy in the treatment of late or recurrent
pulmonary hypertension.
Sedation is an important adjunctive therapy, but the use of paralytic agents remains highly controversial. Although diminished swallowing may be
beneficial, paralysis may promote both atelectasis of dependent lung regions and ventilation-perfusion mismatch, as well as generalized edema and
decreased chest wall compliance.
Surgical Care
Theoretically, fetal surgery for congenital diaphragmatic hernia provides an elegant solution to the difficult problem of congenital diaphragmatic hernia.
Unfortunately, this is far from reality. Harrison et al reported the first human fetal surgery for congenital diaphragmatic hernia in 1990. However, a
randomized trial published in 1998 showed that in utero repair did not improve survival compared with standard therapy. [12 ]
Subsequent trials of fetal intervention focused on occluding the fetal trachea. The fetal lung secretes fluid by active ion transport through gestation, and
this lung fluid provides a template for lung growth. Occlusion of the fetal trachea traps this fluid and stimulates lung growth, either by retention of growth
factors within the lung or stimulation of local growth factors by the gentle distension provided by the fluid. Unfortunately, a randomized trial in humans
found that fetal tracheal occlusion did not improve outcome compared with standard treatment. [13 ]Currently, fetal intervention is not indicated in
congenital diaphragmatic hernia, although some groups continue to offer it on an experimental basis.
Until recently, specialists believed that reduction of the herniated viscera and closure of the diaphragmatic defect should be emergently performed
following birth. However, a delayed surgical approach that enables preoperative stabilization decreases morbidity and mortality. This change in protocol
is due to the recent understanding that the medical problems of pulmonary hypoplasia and PPHN are largely responsible for the outcome of congenital
diaphragmatic hernia and that the severity of these pathophysiologies is largely predetermined in utero. Herniated viscera in the chest does not appear
to exacerbate the pathophysiology as long as bowel decompression with a nasogastric tube is adequate.
Several reports indicate that circulatory stability, respiratory mechanics, and gas exchange deteriorate after surgical repair. The ideal time to repair a
congenital diaphragmatic hernia is unknown. Some suggest that repair 24 hours after stabilization is ideal, but delays of up to 7-10 days are typically
well tolerated, and many surgeons now adopt this approach. Some surgeons prefer to operate on these neonates when normal pulmonary artery
pressure is maintained for at least 24-48 hours based on echocardiography.
Chest tube drainage is necessary when a tension pneumothorax is present; however, whether routine chest drainage following surgical repair has a
role is controversial. Some clinicians report improved survival when chest drainage is not used. Others think that balanced intrathoracic drainage, in
which a closed gated pressure system is used to maintain intrathoracic pressure within the normal physiologic range, may minimize risk of pulmonary
injury and improve respiratory mechanics.
Transplantation of a single lung has been reported in one case. Lung transplantation may allow the remaining hypoplastic lung to grow and to recover
from injury while still allowing adequate oxygenation and ventilation. However, this approach has not been widely used because of the substantial
problems associated with donor lung availability and immunosuppression.
Medication
Medical therapy in congenital diaphragmatic hernia (CDH) is directed toward stabilizing blood pressure and circulating volume, pulmonary distress, and
hypoxemia.
Vasoactive agents
Judicious use of vasoactive agents may increase cardiac output without affecting systemic or pulmonary vascular resistance.
Dopamine (Intropin)
Dopamine increases blood pressure primarily via stimulation of alpha-adrenergic receptors; however, its mechanism of action in newborn infants
remains controversial because of developmental differences in endogenous norepinephrine stores and expression and function of alpha-adrenergic
receptors. Dosage must be individualized.
Dosing
Adult
Pediatric
2-20 mcg/kg/min IV continuous infusion
Interactions
Phenytoin, alpha- and beta-adrenergic blockers, general anesthesia, and MAOIs increase and prolong effects of dopamine
Contraindications
Documented hypersensitivity; pheochromocytoma; ventricular fibrillation
Precautions
Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Precautions
Doses >10 mcg/kg/min may cause pulmonary vasoconstriction; correct hypovolemia prior to infusion; vasoconstriction occurs with IV infiltration,
causing severe local tissue ischemia and sloughing (best administered via central venous catheter)
Dobutamine (Dobutrex)
Increases blood pressure primarily via stimulation of beta1-adrenergic receptors. It appears to have a more prominent effect on cardiac output than on
blood pressure.
Dosing
Adult
Pediatric
2-25 mcg/kg/min IV continuous infusion
Interactions
Beta-adrenergic blockers antagonize effects of dobutamine; general anesthetics may increase toxicity
Contraindications
Documented hypersensitivity; idiopathic hypertrophic subaortic stenosis; atrial fibrillation or flutter
Precautions
Pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions
Hypovolemic state should be corrected before infusion
Milrinone (Primacor)
Bipyridine-positive inotrope and vasodilator with little chronotropic activity. Mode of action differs from that of digitalis glycosides and catecholamines.
Selectively inhibits PDE III in cardiac and smooth vascular muscle, resulting in reduced afterload, reduced preload, and increased inotropy.
Dosing
Adult
Pediatric
Not established, limit data suggest (PALS guidelines): 50 mcg/kg IV loading dose over 10-20 min, followed by continuous IV infusion at 0.375-0.75
mcg/kg/min
Interactions
Milrinone precipitates in presence of furosemide
Contraindications
Documented hypersensitivity to milrinone, any component, or inamrinone
Precautions
Pregnancy
Precautions
Monitor fluids, electrolyte changes, and renal function during therapy; excessive diuresis may increase potassium loss and predispose digitalized
patients to arrhythmias; important to correct hypokalemia with potassium supplementation prior to treatment; patients with excessive decreases in
blood pressure should have infusion rates slowed or stopped; if previous vigorous diuretic therapy has caused significant decreases in cardiac filling
pressure, cautiously administer milrinone and monitor blood pressure, heart rate, and clinical symptomatology
Opioid analgesics
These agents are used for deep sedation to allow adequate mechanical ventilation. They may be particularly useful in decreasing sympathetic
pulmonary vasoconstriction in response to noxious stimuli, such as suctioning.
Fentanyl (Duragesic, Sublimaze)
Synthetic opioid that is 75-200 times more potent than morphine. It is highly lipophilic and protein-bound. Prolonged exposure leads to accumulation in
fat and delays the weaning process. Used alone, fentanyl causes minor cardiovascular compromise, although the addition of benzodiazepines or other
sedatives may result in decreased cardiac output and blood pressure.
Dosing
Adult
Pediatric
Intermittent: 1-5 mcg/kg IV q2h by slow bolus

Continuous infusion: 1-10 mcg/kg/min IV
Interactions
Phenothiazines may antagonize analgesic effects of opiate agonists; tricyclic antidepressants may potentiate adverse effects of fentanyl when both
drugs are used concurrently
Contraindications
Documented hypersensitivity; hypotension; potentially compromised airway when establishing rapid airway control would be difficult
Precautions
Pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions
Caution in hypotension, respiratory depression, constipation, nausea, emesis, and urinary retention; acute muscle rigidity (chest syndrome) may
occur following rapid infusion; tolerance develops rapidly; withdrawal symptoms may develop if used for >5 d
Neuromuscular relaxing agents

Paralysis is sometimes necessary in an infant who is unstable despite adequate sedation; however, the use of paralysis is controversial and should be
reserved for unusual cases in which the infant cannot be treated with appropriate sedation.
Pancuronium (Pavulon)
Relatively long-acting nondepolarizing muscle relaxant. Onset of action is 1-2 min, and duration of action is 45-90 min. Excretion is renal (80%) and
hepatic (20%), and duration of action may be longer if renal or hepatic failure is present.
Dosing
Adult
Pediatric
0.05-0.15 mg/kg/dose IV bolus
Interactions
Increased effect with magnesium sulfate, furosemide, aminoglycosides, amphotericin, ketamine, cyclosporine, inhalation anesthetics, or
antiarrhythmics; decreased effect with calcium, carbamazepine, phenytoin, corticosteroids, theophylline, or caffeine
Contraindications
Documented hypersensitivity; myasthenia gravis or related syndromes
Precautions
Pregnancy
Precautions
May cause tachycardia, hypotension, and excessive salivation; caution with conditions that may potentiate neuromuscular blockade (eg, electrolyte
abnormalities, neuromuscular disease, acidosis, renal or hepatic failure)
Vecuronium (Norcuron)
Has few to no adverse hemodynamic adverse effects and may be preferred over pancuronium as a muscle relaxant in the infant with PPHN; however, it
is more expensive than pancuronium.
Intermediate-acting nondepolarizing muscle relaxant. Onset of action is 1-2 min, and duration of action is 45-90 min. Primary route of excretion is
hepatic.
Dosing
Adult
Pediatric
0.05-0.15 mg/kg/dose IV q1-2h; alternatively, may be used as a continuous infusion
Interactions
Increased effect with magnesium sulfate, furosemide, aminoglycosides, amphotericin, ketamine, cyclosporine, inhalation anesthetics, or
antiarrhythmics; decreased effect with calcium, carbamazepine, phenytoin, corticosteroids, theophylline, or caffeine
Contraindications
Documented hypersensitivity; myasthenia gravis or related syndromes
Precautions
Pregnancy
Precautions
In myasthenia gravis or myasthenic syndrome, small doses of vecuronium may have profound effects; caution with conditions that may potentiate
neuromuscular blockade (eg, electrolyte abnormalities, neuromuscular disease, acidosis, hepatic failure)
Pulmonary vasodilating agents

Nitric oxide is an important mediator of vascular tone that was recently approved as a therapeutic modality for infants with PPHN. It is delivered as an
inhaled gas. At least 2 multicenter studies did not show that inhaled nitric oxide decreases mortality or the need for extracorporeal support in infants
with CDH; however, it may be useful in stabilizing an infant while evaluating or transferring for ECMO.
Nitric oxide (INOmax)
The FDA approved nitric oxide for the treatment of PPHN in December 1999. Produced endogenously from action of enzyme NO synthetase on
arginine. Relaxes vascular smooth muscle by binding to heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing
intracellular levels of cGMP, which then leads to vasodilation. When inhaled, NO decreases pulmonary vascular resistance and improves lung blood
flow.
Optimal dose is unknown, although most investigators agree that doses >20 ppm are not beneficial and may be harmful. Administration should occur
under controlled conditions, with access to ECMO if needed. NO2 and methemoglobin levels should be frequently monitored, and weaning should
gradually occur. Abrupt discontinuation may be associated with severe rebound pulmonary hypertension.
Dosing
Adult
Pediatric
1-20 ppm inhalation

Deliver by system that measures concentrations of NO in breathing gas, with constant concentration throughout respiratory cycle, and that does not
cause generation of excessive inhaled nitrogen dioxide
Interactions
Concomitant administration with NO donor compounds (eg, nitroprusside, nitroglycerin) may have additive effects and increase risk of
methemoglobinemia
Contraindications
Right-to-left shunting of blood; methemoglobin reductase deficiency
Precautions
Pregnancy
Precautions
Methemoglobinemia and pulmonary inflammation resulting from reactive nitrogen intermediates; abrupt discontinuation of NO may lead to worsening
oxygenation and increasing PAP; toxic effects include methemoglobinemia and pulmonary inflammation resulting from reactive nitrogen intermediates;
caution in thrombocytopenia, anemia, leukopenia, or bleeding disorders; monitor for PaO2, methemoglobin, and NO2; abrupt withdrawal causes
rebound pulmonary hypertension
Follow-up
Further Inpatient Care
Pulmonary care in congenital diaphragmatic hernia (CDH)
Severely affected infants have chronic lung disease. These infants may require prolonged therapy with supplemental oxygen and diuretics, an approach
similar to that for bronchopulmonary dysplasia. The use of steroids, particularly high doses for prolonged periods, is controversial and may hinder
appropriate lung and brain development.
Late pulmonary hypertension has been successfully treated with low-dose inhaled nitric oxide. This therapy can be delivered via nasal cannula
following extubation. In this setting, the delivered dose is diluted because of entrainment of room air. In a recent report, the median duration of
treatment using inhaled nitric oxide delivered via nasal cannula was 17 days.
Case reports are now emerging regarding the use of other pulmonary vasodilators, such as sildenafil and endothelin receptor antagonists. Systemic
study is required to assess the sustained benefit.
Neurologic evaluation
Following recovery, a neurologist or developmental pediatrician should perform an examination that includes an evaluation for CNS injury using head CT
scanning or MRI.
The incidence of hearing loss appears to be particularly high in patients with congenital diaphragmatic hernia (approximately 40% of infants). An
automated hearing test should be performed prior to discharge.
Gastroesophageal reflux
The incidence of significant gastroesophageal reflux is very high in patients who survive congenital diaphragmatic hernia, and studies document an
incidence of 45-85%.
The need for a diaphragmatic patch may be a significant predictor of gastroesophageal reflux. Severe reflux may result in chronic aspiration and is,
therefore, aggressively treated.
Although most infants can be medically treated with H2-blockers or proton pump inhibitors in combination with a motility agent such as
metoclopramide, surgical intervention is sometimes required.
Further Outpatient Care

Failure to thrive is common, and, in some studies, more than 50% of patients are below the 25th percentile for height and weight during the first year of
life. In one study, one third of infants required gastrostomy tube placement to improve caloric intake. The need for supplemental oxygen at the time of
discharge is a significant predictor for subsequent growth failure. Possible causes include increased caloric requirements due to chronic lung disease,
oral aversion after prolonged intubation, poor oral feeding due to neurologic delays, and gastroesophageal reflux.
Because of the risk for CNS insult and sensorineural hearing loss, infants should be closely monitored for the first 3 years of life, [14 ]preferably in a
specialty follow-up clinic. These risks are particularly high in infants who are discharged home on supplemental oxygen. Reassess hearing at age 6
months (and later if indicated) because late sensorineural hearing loss occurs in approximately 40% of patients.
Even if a child has no major neurodevelopmental delays, he or she should be evaluated prior to entering school to determine if any subtle deficits may
predispose the child to learning disabilities.
Transfer
Guidelines for ECMO consultation are available from the ELSO. Baseline criteria for ECMO consideration include evaluation for risk factors because of
the invasive nature of the therapy and need for heparinization. Although criteria are center-specific, infants should generally be older than 34 weeks'
gestation, have a weight greater than 2000 g, have no major intracranial hemorrhage on cranial sonography, have been on mechanical ventilator support
for fewer than 10-14 days, and have no evidence for lethal congenital anomalies or inoperable cardiac disease.
Timing is always difficult, but referral and transfer should occur prior to refractory hypoxia. Early consultation and discussion with the ECMO center is
strongly recommended.
Prognosis
Overall reported survival varies among institutions. Remember that a single institution's results may look better than those provided by population-
based studies because of case-selection biases. When all resources, including ECMO, are provided, reported survival rates range from 40-90%. The
ELSO registry reports the ECMO survival rate at 52%.
As noted, survivors are at risk for significant long-term morbidity, including chronic lung disease, growth failure, gastroesophageal reflux, hearing loss,
and neurodevelopmental delay. The risk appears to be highest in infants with severe lung disease (need for long term supplemental oxygen), need for
patch closure of the diaphragm, and need for gastrostomy tube feeding.
Miscellaneous
Special Concerns
Using ultrasonography, congenital diaphragmatic hernia (CDH) may be prenatally diagnosed as early as the second trimester.[15 ]Suggestive findings
include polyhydramnios, an absent or intrathoracic stomach bubble, and mediastinal and cardiac shift. A detailed examination (level II ultrasonography)
is typically necessary.
Prenatal diagnosis allows for chromosomal analysis and screening for other anomalies prior to the infant's birth. In addition, it allows the mother time to
make important decisions about the pregnancy, including delivery in a facility with a neonatal ICU (NICU) that offers advanced respiratory support for
the newborn infant.
Developing meaningful prognostic information before birth continues to be difficult. Some advocate for assessment of lung hypoplasia using ultrasound
measurements of liver herniation into the thorax, lung to head ratios (LHR), or pulmonary artery to aorta ratios (modified McGoon index). MRI of the
fetus is a promising technique that allows more precise measurement of the lung volume indexed to the body volume. [16 ]
Multimedia
Media file 1: Radiograph of a 1-day-old infant with a moderate-sized congenital diaphragmatic hernia (CDH). Note the air- and
fluid-filled bowel loops in the left chest, the moderate shift of the mediastinum into the right chest, and the position of the
orogastric tube.
References
1. Gross RE. Congenital hernia of the diaphragm. Am J Dis Child. 1946;71:579-592.
2. Areechon W, Reid L. Hypoplasia of the lung associated with congenital diaphragmatic hernia. Br Med J. 1963;i:230-3.
3. Klaassens M, de Klein A, Tibboel D. The etiology of congenital diaphragmatic hernia: still largely unknown?. Eur J Med Genet. Sep-
Oct 2009;52(5):281-6. [Medline].
4. Jandus P, Savioz D, Purek L, Frey JG, Schnyder JM, Tschopp JM. [Bochdalek hernia: a rare cause of dyspnea and abdominal pain in
adults]. Rev Med Suisse. May 13 2009;5(203):1061-4. [Medline].
5. Fisher JC, Haley MJ, Ruiz-Elizalde A, Stolar CJ, Arkovitz MS. Multivariate model for predicting recurrence in congenital diaphragmatic hernia. J
Pediatr Surg. Jun 2009;44(6):1173-9; discussion 1179-80. [Medline].
6. [Best Evidence] Keller RL, Tacy TA, Hendricks-Munoz K, et al. Congenital diaphragmatic hernia: endothelin-1, pulmonary hypertension, and
disease severity. Am J Respir Crit Care Med. Aug 15 2010;182(4):555-61. [Medline]. [Full Text].
7. Clugston RD, Zhang W, Alvarez S, De Lera AR, Greer JJ. Understanding Abnormal Retinoid Signaling as a Causative Mechanism in Congenital
Diaphragmatic Hernia. Am J Respir Cell Mol Biol. May 15 2009;[Medline].
8. Bryner BS, West BT, Hirschl RB, et al. Congenital diaphragmatic hernia requiring extracorporeal membrane oxygenation: does timing of repair
matter?. J Pediatr Surg. Jun 2009;44(6):1165-71; discussion 1171-2. [Medline].
9. Deprest JA, Gratacos E, Nicolaides K, et al. Changing perspectives on the perinatal management of isolated congenital diaphragmatic hernia in
Europe. Clin Perinatol. Jun 2009;36(2):329-47, ix. [Medline].
10. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation
and outcomes. Pediatrics. Jan 2000;105(1 Pt 1):14-20. [Medline].
11. Fliman PJ, deRegnier RA, Kinsella JP, Reynolds M, Rankin LL, Steinhorn RH. Neonatal extracorporeal life support: impact of new therapies on
survival. J Pediatr. May 2006;148(5):595-9. [Medline].
12. Harrison MR, Keller RL, Hawgood SB, et al. A randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic
hernia. N Engl J Med. Nov 13 2003;349(20):1916-24. [Medline].
13. Jelin E, Lee H. Tracheal occlusion for fetal congenital diaphragmatic hernia: the US experience. Clin Perinatol. Jun 2009;36(2):349-61,
ix. [Medline].
14. Peetsold M, Huisman J, Hofman VE, Heij HA, Raat H, Gemke RJ. Psychological outcome and quality of life in children born with congenital
diaphragmatic hernia. Arch Dis Child. Jun 15 2009;[Medline].
15. Mitanchez D. [Neonatal prognosis of congenital diaphragmatic hernia]. Arch Pediatr. Jun 2009;16(6):888-90. [Medline].
16. Keller RL. Antenatal and postnatal lung and vascular anatomic and functional studies in congenital diaphragmatic hernia: implications for clinical
management. Am J Med Genet C Semin Med Genet. May 15 2007;145C(2):184-200. [Medline].
17. [Guideline] Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial diseases. European Society
of Cardiology. 2004.
18. Albanese CT, Lopoo J, Goldstein RB, et al. Fetal liver position and perinatal outcome for congenital diaphragmatic hernia. Prenat
Diagn. Nov 1998;18(11):1138-42. [Medline].
19. Bohn DJ, Pearl R, Irish MS, Glick PL. Postnatal management of congenital diaphragmatic hernia. Clin Perinatol. Dec 1996;23(4):843-
72. [Medline].
20. Clark RH, Hardin WD Jr, Hirschl RB, et al. Current surgical management of congenital diaphragmatic hernia: a report from the Congenital
Diaphragmatic Hernia Study Group. J Pediatr Surg. Jul 1998;33(7):1004-9. [Medline].
21. Colvin J, Bower C, Dickinson JE, Sokol J. Outcomes of congenital diaphragmatic hernia: a population-based study in Western
Australia. Pediatrics. Sep 2005;116(3):e356-63. [Medline]. [Full Text].
22. Cortes RA, Keller RL, Townsend T, et al. Survival of severe congenital diaphragmatic hernia has morbid consequences. J Pediatr
Surg. Jan 2005;40(1):36-45; discussion 45-6. [Medline].
23. Finer NN, Tierney A, Etches PC, Peliowski A, Ainsworth W. Congenital diaphragmatic hernia: developing a protocolized approach. J Pediatr
Surg. Sep 1998;33(9):1331-7. [Medline].
24. Garred P, Madsen HO, Balslev U, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding
lectin. Lancet. Jan 25 1997;349(9047):236-40. [Medline].
25. Kapur P, Holm BA, Irish MS, Patel A, Glick PL. Tracheal ligation and mechanical ventilation do not improve the antioxidant enzyme status in
the lamb model of congenital diaphragmatic hernia. J Pediatr Surg. Feb 1999;34(2):270-2. [Medline].
26. Kays DW, Langham MR Jr, Ledbetter DJ, Talbert JL. Detrimental effects of standard medical therapy in congenital diaphragmatic hernia. Ann
Surg. Sep 1999;230(3):340-8; discussion 348-51. [Medline]. [Full Text].
27. Kinsella JP, Parker TA, Ivy DD, Abman SH. Noninvasive delivery of inhaled nitric oxide therapy for late pulmonary hypertension in newborn
infants with congenital diaphragmatic hernia. J Pediatr. Apr 2003;142(4):397-401. [Medline].
28. Lally KP. Extracorporeal membrane oxygenation in patients with congenital diaphragmatic hernia. Semin Pediatr Surg. Nov 1996;5(4):249-
55. [Medline].
29. Lally KP, Breaux CW Jr. A second course of extracorporeal membrane oxygenation in the neonate--is there a
benefit?. Surgery. Feb 1995;117(2):175-8. [Medline].
30. Lally KP, Lally PA, Langham MR, et al. Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia. J
Pediatr Surg. Jun 2004;39(6):829-33. [Medline].
31. Langham MR Jr, Kays DW, Ledbetter DJ, Frentzen B, Sanford LL, Richards DS. Congenital diaphragmatic hernia. Epidemiology and
outcome. Clin Perinatol. Dec 1996;23(4):671-88. [Medline].
32. NINOS. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide
Study Group (NINOS). Pediatrics. Jun 1997;99(6):838-45. [Medline]. [Full Text].
33. Nobuhara KK, Lund DP, Mitchell J, Kharasch V, Wilson JM. Long-term outlook for survivors of congenital diaphragmatic hernia. Clin
Perinatol. Dec 1996;23(4):873-87. [Medline].
34. Nobuhara KK, Wilson JM. Pathophysiology of congenital diaphragmatic hernia. Semin Pediatr Surg. Nov 1996;5(4):234-42. [Medline].
35. O'Toole SJ, Irish MS, Holm BA, Glick PL. Pulmonary vascular abnormalities in congenital diaphragmatic hernia. Clin
36. Reickert CA, Hirschl RB, Atkinson JB, et al. Congenital diaphragmatic hernia survival and use of extracorporeal life support at selected level III
nurseries with multimodality support. Surgery. Mar 1998;123(3):305-10. [Medline].
37. Slavotinek AM. The genetics of congenital diaphragmatic hernia. Semin Perinatol. Apr 2005;29(2):77-85. [Medline].
38. Stege G, Fenton A, Jaffray B. Nihilism in the 1990s: the true mortality of congenital diaphragmatic hernia. Pediatrics. Sep 2003;112(3 Pt 1):532-
5. [Medline]. [Full Text].
39. Steinhorn RH, Kriesmer PJ, Green TP, McKay CJ, Payne NR. Congenital diaphragmatic hernia in Minnesota. Impact of antenatal diagnosis on
survival. Arch Pediatr Adolesc Med. Jun 1994;148(6):626-31. [Medline].
40. Stolar CJ. What do survivors of congenital diaphragmatic hernia look like when they grow up?. Semin Pediatr Surg. Nov 1996;5(4):275-
9. [Medline].
41. Van Meurs K. Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia?. J
Pediatr. Sep 2004;145(3):312-6. [Medline].
42. Weinstein S, Stolar CJ. Newborn surgical emergencies. Congenital diaphragmatic hernia and extracorporeal membrane oxygenation. Pediatr
Clin North Am. Dec 1993;40(6):1315-33. [Medline].
43. Wilcox DT, Irish MS, Holm BA, Glick PL. Pulmonary parenchymal abnormalities in congenital diaphragmatic hernia. Clin
44. Wilson JM, Lund DP, Lillehei CW, Vacanti JP. Congenital diaphragmatic hernia--a tale of two cities: the Boston experience. J Pediatr
Surg. Mar 1997;32(3):401-5. [Medline].
Keywords
congenital diaphragmatic hernia, CDH, pulmonary hypoplasia, pulmonary hypertension, Cornelia de Lange syndrome, cleft lip, cleft palate,
pneumothorax, polyhydramnios, respiratory distress, cyanosis, Turner syndrome, treatment, diagnosis
Contributor Information and Disclosures

Author
Robin H Steinhorn, MD, Raymond and Hazel Speck Berry Professor of Pediatrics, Division Head of Neonatology, Associate Chair of Pediatrics,
Northwestern University School of Medicine
Robin H Steinhorn, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Heart
Association, American Pediatric Society, American Thoracic Society, and Society for Pediatric Research
Disclosure: Ikaria (INO Therapeutics) Consulting fee Consulting
Coauthor(s)
Nicolas FM Porta, MD, FAAP, Assistant Professor, Department of Pediatrics, Northwestern University, The Feinberg School of Medicine
Nicolas FM Porta, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics
Disclosure: United Therapeutics Consulting fee Consulting
Medical Editor
David N Sheftel, MD, Director, Division of Neonatology, Clinical Associate Professor, Department of Pediatrics, Lutheran General Children's Hospital
of Park Ridge, Chicago Medical School
David N Sheftel, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine and American
Academy of Pediatrics
Disclosure: Nothing to disclose.
Pharmacy Editor
Mary L Windle, PharmD, Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine
Managing Editor
Arun K Pramanik, MD, MBBS, Professor of Pediatrics, Director of Neonatal Fellowship, Louisiana State University Health Sciences Center
Arun K Pramanik, MD, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, National
Perinatal Association, and Southern Society for Pediatric Research
CME Editor
Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina
Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical
Women's Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Clinical Nutrition,
Massachusetts Medical Society, National Perinatal Association, and Society for Pediatric Research
Chief Editor
Ted Rosenkrantz, MD, Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of
Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American
Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research
Further Reading
Relevant clinical guidelines include Guidelines on the diagnosis and management of pericardial diseases. The task f orce on the diagnosis and management of pericardial
diseases of the European Society of Cardiology [ 17 ]
Relevant clinical trials include the f ollow ing:
Randomized Control Trial of Fetoscopic Endoluminal Tracheal Occlusion With a Balloon Versus Expectant Management During Pregnancy in Fetuses With Left
Sided Congenital Diaphragmatic Hernia and Moderate Pulmonary Hypoplasia. (TOTAL)
Percutaneous Endoscopic Tracheal Plug/Unplug for CDH
Fetoscopic Tracheal Balloon Occlusion in Left Diaphragmatic Hernia
Related eMedicine topics include the follow ing:
Congenital Diaphragmatic Hernia (Radiology)
Diaphragmatic Hernias (Pediatrics: Surgery)
Diaphragmatic Hernias, Congenital (Thoracic Surgery)
Hiatal Hernia
Chest Wall Def ormities
© 1994-2010 by Medscape.
All Rights Reserved
(http://w w w .medscape.com/public/copyright)

Diafragmatic Hernia

Hochgeladen von

Dokumentinformationen

Originalbeschreibung:

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Diafragmatic Hernia

Hochgeladen von

Copyright:

Verfügbare Formate

11/8/2010 Congenital Diaphragmatic Hernia: [Print] - eMedicin…

Congenital Diaphragmatic Hernia

Other Problems to Be Considered

2-20 mcg/kg/min IV continuous infusion

Documented hypersensitivity; pheochromocytoma; ventricular fibrillation

2-25 mcg/kg/min IV continuous infusion

Documented hypersensitivity; idiopathic hypertrophic subaortic stenosis; atrial fibrillation or flutter

Hypovolemic state should be corrected before infusion

Milrinone precipitates in presence of furosemide

Documented hypersensitivity to milrinone, any component, or inamrinone

Fentanyl (Duragesic, Sublimaze)

Intermittent: 1-5 mcg/kg IV q2h by slow bolus

Neuromuscular relaxing agents

0.05-0.15 mg/kg/dose IV bolus

0.05-0.15 mg/kg/dose IV q1-2h; alternatively, may be used as a continuous infusion

Documented hypersensitivity; myasthenia gravis or related syndromes

Pulmonary vasodilating agents

Nitric oxide (INOmax)

1-20 ppm inhalation

Right-to-left shunting of blood; methemoglobin reductase deficiency

Further Outpatient Care

Contributor Information and Disclosures

Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina

Das könnte Ihnen auch gefallen